Zai Lab Limited EBIT

As of the most recent data (June 2026), ZLAB shows a EBIT of $-220M. That compares with $-240M in the prior-year period — up 6.7% year over year. That is below the Healthcare sector average of $23B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ZLAB's EBIT is now $-220M (was $-240M) — a 6.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Zai Lab Limited is outperforming or lagging.

The Healthcare sector average EBIT is about $23B. Zai Lab Limited is at $-220M, which is lower that average. That is roughly 101.0% below the sector mean. Use the comparison chart on this page to see how ZLAB stacks up against individual peers as well.

Tracking ZLAB's ebit over time shows whether Zai Lab Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $-220M That compares with $-240M in the prior-year period — up 6.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Zai Lab Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-220M) with ownership activity and broader fundamentals.